Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects.

Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Tsougos I, Theodorou K, Georgoulias P, Gourgoulianis KI, Germenis AE.

J Exp Clin Cancer Res. 2010 Jun 4;29:64. doi: 10.1186/1756-9966-29-64.

4.
5.

Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.

Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.

Oncol Rep. 2004 Oct;12(4):725-31.

PMID:
15375491
7.

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM.

Blood. 2001 Feb 15;97(4):835-43.

8.

CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.

Karagöz B, Bilgi O, Gümüs M, Erikçi AA, Sayan O, Türken O, Kandemir EG, Oztürk A, Yaylaci M.

Med Oncol. 2010 Mar;27(1):29-33. doi: 10.1007/s12032-008-9165-9. Epub 2009 Jan 16.

PMID:
19148592
9.

Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.

Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM.

J Immunol. 2002 Jan 15;168(2):909-18.

11.

Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.

Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ.

J Exp Med. 1996 Mar 1;183(3):1215-28. Erratum in: J Exp Med 1996 Sep 1;184(3):1199.

12.

Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.

Tsuge I, Morishima T, Kimura H, Kuzushima K, Matsuoka H.

J Med Virol. 2001 Jun;64(2):141-8.

PMID:
11360246
13.
14.

Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.

Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA.

Brain. 2008 Jul;131(Pt 7):1712-21. doi: 10.1093/brain/awn108. Epub 2008 Jun 11.

PMID:
18550621
15.

Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus.

Kang I, Quan T, Nolasco H, Park SH, Hong MS, Crouch J, Pamer EG, Howe JG, Craft J.

J Immunol. 2004 Jan 15;172(2):1287-94.

16.

Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.

Klatt T, Ouyang Q, Flad T, Koetter I, Bühring HJ, Kalbacher H, Pawelec G, Müller CA.

J Rheumatol. 2005 Feb;32(2):239-51.

PMID:
15693083
17.

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglass J, Williams T, Elliott SL, Moss DJ.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10391-6.

18.

A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events.

Haque T, Thomas JA, Parratt R, Hunt BJ, Yacoub MH, Crawford DH.

Transplantation. 1997 Oct 15;64(7):1028-34.

PMID:
9381525
19.

Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells.

Takenoyama M, Yoshino I, Fujie H, Hanagiri T, Yoshimatsu T, Imabayashi S, Eifuku R, Nomoto K, Yasumoto K.

Jpn J Cancer Res. 1998 Jan;89(1):60-6.

PMID:
9510477

Supplemental Content

Support Center